Beta
Back to LLY.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • Revenue by Segments
  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
eps-diluted-chart

LLY EPS Diluted

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for LLY's diluted EPS in Q4'25 stands at 7.39 USD, marking a significant year-over-year growth of 51.43% and reflecting robust profitability in the final quarter of the fiscal year. Over the period from Q1'23 to Q4'25, LLY's diluted EPS exhibited strong overall growth, rising from 1.49 USD to 7.39 USD despite notable volatility, including a sharp decline to -0.06 USD in Q3'23 and fluctuations in Q3'24 (1.07 USD) and Q1'25 (3.06 USD). Year-over-year growth rates were predominantly positive, with exceptional surges such as 1,883% in Q3'24 and 480% in Q3'25, underscoring accelerating earnings momentum driven by key product contributions, while the bar chart highlights consistent quarterly improvements post-2023 lows. This trend indicates sustained operational strength and potential for continued expansion in the pharmaceutical sector.